From a safety standpoint, retatrutide's known adverse effect profile from phase II trials includes: Nausea, vomiting, and diarrhoea (gastrointestinal effects common to GLP-1 receptor agonists) Reduced appetite and potential nutritional deficiencies with prolonged use Elevated heart rate observed in some trial participants Pancreatitis and gallbladder disease , which are recognised class cautions for GLP-1based therapies and should be considered in the context of retatrutide, although retatrutide-specific data remain limited Thyroid C-cell changes , observed in rodent studies with GLP-1 receptor agonists
Change the water volume in the calculator above to recompute for your own setup
How Weight, Inflammation, and Metabolic Stress Are Connected Infections or injuries do not always cause inflammation
Patients with type 2 diabetes who are prescribed tirzepatide for glycemic control may also have dyslipidemia requiring lipid-modifying therapy
How much more effective is it than semaglutide alone
Others focus on payout speed and helpfulness of support staff